Introduction
The activating transcription factor 3 (ATF3), as a member of the ATF/CREB subfamily, is a stress-inducible gene, whose expression is rapidly induced by a wide range of cellular stresses including DNA damage, cellular injury and oxidative stress [1, 2] . It belongs to a basic leucine-chemotherapy or radiation therapy. This project was approved by the Research Ethics Committee of Chengdu Second People's Hospital. Informed consent was obtained from each patient.
Cell lines and cell culture
HepG2 cells were grown in DMEM supplemented with 10% fetal bovine serum (Life Technology) according to ATCC protocols. Cells were maintained in a humidified incubator at 37°C and 5% CO 2 .
RNA preparation and Quantitative Real Time PCR
Total RNA was extracted with Trizol reagents (Life technologies) as per manufacturer's instruction. Reverse transcription was performed with reverse transcription kit (Promega). Briefly, 2 μg total RNA was used as template to synthesize the first strand of cDNA with M-MLV reverse transcriptase in a 20 μl reaction system. Real time PCR was performed with SYBR Green Mix (TAKARA) on ABI 7500 system (Life technologies). Data were normalized to GAPDH expression and primers were synthesized by Shanghai Sangon Company. The sequences of PCR primers used in this study were as follows:
GAPDH-F: ATTGCCCTCAACGACCACTT, -R: CCCTGTTGCTGTAGCCAAATTC ATF3-F: CTCTGCGCTGGAATCAGTCA, -R: GGCTACCTCGGCTTTTGTGA cyclin D1-F: ACCTGAGGAGCCCCAACAAC, -R: GTCCGGGTCACACTTGATC.
SDS-PAGE and Western blot
Total cell lysate was extracted from cells by RIPA buffer. After boiling for 5min at 100°C, protein samples were loaded onto a 12% SDS-PAGE gel. After migration, proteins were transferred to NC membrane (Amersham Bioscience). Then the membrane was blocked in PBS containing 0.05% Tween-20 and 5% non-fat milk. After washing for three times the membrane was incubated with primary antibodies: anti-ATF3, anti-cyclin D1 and anti-Actin (Santa Cruz) at 4°C over night. After washing for three times, the blots were incubated with certain secondary antibodies (Pierce) at RT for 2 h. Finally, the protein-antibody complexes were visualized by a chemiluminescence detection system (Milipore).
Short interfering RNAs and transfections
ATF3 siRNA and control siRNA were purchased from Santa Cruz. Transfections were performed by Lipofectamin2000 as per the manufacturer's instruction. Sequences of ATF3 siRNA were: UCCUGGGUCACUGGUGUUUdTdT.
Plasmids construction
The pcDNA3.0 plasmid was purchased from Life Technology Company. ATF3 coding region was amplified by PCR and cloned into pcDNA3.0 plasmids with specific restriction enzymes by adding an HA tag.
MTT assay
Hep2G cells were transfected with ATF3 over-expression plasmid or control plasmid at varying time: Day1 (D1), Day2 (D2), Day3 (D3) and Day4 (D4). Then, 20 μl of sterile MTT (5 mg/ml, sigma) was added and incubation for another 4 h at 37°C. Then, 150 μl of DMSO was added to each well and the contents of the plates were thoroughly mixed for 10 min. Spectrometric absorbance at a wavelength of 490 nm was measured on a microplate reader.
Statistical analysis
All calculations and statistical analyses were performed using Microsoft Excel 2007 or Graphpad Prism v5 software. Student's t test was used to compare paired or grouped data in experiments. Linear regression was used to analyze the correlation between genes. All data are presented as average ± SD. A P values less than 0.05 was considered to be statistically significant.
Results

Expression of ATF3 was decreased in HCC specimens
Real time PCR was firstly used to detect the mRNA level of ATF3 in 30 pairs of human HCC specimens. The results shown in Figure 1A suggest that ATF3 mRNA was is significantly lower in cancerous HCC tissues (P < 0.05).
In addition, to further explore its protein expression, we randomly selected 6 pairs HCC specimens from the above 30 pairs of samples, and total protein was extracted for western blot to analyze its expression. As shown in Figure  1B , our results confirmed its downregulation in HCC specimens.
ATF3-overexpressing inhibited cell proliferation of HepG2 cells
After verifying the lower expression of ATF3 in HCC, we then set out to determine its role in cell proliferation. HepG2 was used and ATF3 was overexpressed by plasmid transfection. After confirming the overexpression efficiency by both real time PCR and western blot ( Figure  2A and 2B) , MTT assay was performed to quantify the cellular growth rate of HepG2 cells for 4 days. The results showed that ATF3 overexpression in HepG2 cells could led to an obvious decrease in cell viability and slow growth rate than the vector-expressing cells (P < 0.05, Figure 2C ). 
ATF3 negatively regulated cyclin D1 expression
From the above results, we concluded that ATF3 inhibited cell proliferation. Next, to determine the growth-related molecule-cyclin D1 expression in ATF3-overexpressing cells, real time PCR was also performed to analyze the cyclin D1 mRNA. The results showed that cyclin D1 was reduced in ATF3-overexpressing HepG2 cells (Figure 3A,  left) . In addition, using ATF3-targeted siRNA, we found that cyclin D1 was elevated in ATF3-siRNA transfected cells than that of control cells (Figure 3A, right) . Most importantly, we validated the upregulation of cyclin D1 in the above-mentioned 30 pairs of HCC specimens ( Figure  3B ) and there was a negative correlation between ATF3 and cyclinD1 mRNA expression in these samples ( Figure  3C , n = 30, P < 0.001).
Discussion
ATF3 exerts transcriptional repressing or activating activities in a context-and cell type-dependent manner [9, 10] . Surprisingly, recent studies have unveiled crucial but controversial roles of ATF3 in human cancers [11] .
Although it was previously shown to be a metastasis promoter in a murine B16 melanoma model, other groups have found that ATF3 could suppress invasion and metastasis of lung and bladder cancers [12, 13] . Similarly, ATF3 may be oncogenic as it can be protective against apoptosis, but it was found to be induced following DNA damage in colon cancer cells and suppressed the growth of HeLa cells [14, 15] . The occurrence of HCC is as complicated as other malignant tumors. In HCC, ATF3 was found to be expressed at lower levels in HCC and lower expression was seen in patients with capsule invasion [16] . This finding indicates that ATF3 may serve as a tumor suppressor during human hepatocellular oncogenesis but direct evidence was lacking at that time. Besides, in a more recent study, Weng et al. showed that niclosamide, an antihelminthic drug for treatment of tapeworm infections approved by FDA, could induce cell apoptosis via upregulating ATF3 and they further demonstrated that ATF3 played an integral role in ER stress activated and cell apoptosis induced by niclosamide in HCC cells [17] . All these findings suggested an anti-tumor role of ATF3 in HCC. We noticed that the cell proliferation ability of HCC cells was not investigated so far. Hence, our attempt to evaluate its role in cell growth of HCC was to provide useful information to some extent.
In this study, we validated that ATF3 mRNA and protein expression was downregulated in HCC specimens. Our novel finding was to show its anti-growth activity in HCC cells, since overexpression of ATF3 caused cell proliferation arrest. The results were the same as another report in esophageal squamous cell carcinoma (ESCC), in which they also found ATF3 was decreased in ESCC and colony formation as well as tumor formation were inhibited by ATF3 overexpression [18] . We speculate that negative regulation of cyclin D1 by ATF3 is responsible for its tumor suppressor function in HCC. However, how ATF3 impacts on the expression of cyclin D1 remains to be further studied.
Taken together, our findings demonstrate that ATF3 was downregulated in HCC and functioned as a tumor suppressor to inhibit cell growth. Moreover, we suggested that these growth inhibitory effects of ATF3 might be related with cylin D1 signaling. Our data supported that targeting ATF3 pathway might be beneficial for anti-HCC therapy.
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